SCHEMBL4379032

SCHEMBL4379032

CCCN1CCN(C(=O)C=Cc2cc(C(C)(C)C)c(O)c(C(C)(C)C)c2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR183 P32249 3/20 0.51
GABBR2 O75899 2/20 0.49
GABBR1 Q9UBS5 2/20 0.49
ALDH1A1 P00352 5/20 0.46
HPGD P15428 2/20 0.46
ALOX15 P16050 1/20 0.46
ALOX12 P18054 1/20 0.46
HSD17B10 Q99714 1/20 0.46
APOBEC3G Q9HC16 1/20 0.46
GAA P10253 2/20 0.46
POLB P06746 2/20 0.45
TDP1 Q9NUW8 1/20 0.45
MAOA P21397 2/20 0.44
MAOB P27338 2/20 0.44
KDM4E B2RXH2 2/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
LMNA P02545 1/20 0.43
THRB P10828 1/20 0.43
TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14190908 1.00 GPR183 (0.51) GPR183GABBR2GABBR1ALDH1A1HPGD
SCHEMBL10898734 0.82 EBP (0.46) GPR183GABBR2GABBR1ALDH1A1HPGD
SCHEMBL10900963 0.82 MAOA (0.45) GPR183GABBR2GABBR1POLBMAOA
SCHEMBL10898730 0.82 EBP (0.46) GPR183GABBR2GABBR1ALDH1A1HPGD
SCHEMBL10900958 0.82 MAOA (0.45) GPR183GABBR2GABBR1POLBMAOA
SCHEMBL10898379 0.81 MAOA (0.42) GPR183ALDH1A1HPGDGAATDP1
SCHEMBL10898376 0.81 MAOA (0.42) GPR183ALDH1A1HPGDGAATDP1
SCHEMBL14190910 0.80 ALDH1A1 (0.67) GPR183ALDH1A1HPGDGAAPOLB
SCHEMBL4375408 0.80 ALDH1A1 (0.67) GPR183ALDH1A1HPGDGAAPOLB
SCHEMBL10901691 0.80 KCNJ1 (0.50) GPR183ALDH1A1HPGDTDP1MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1421071-B1 SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS HIGH POINT PHARMACEUTICALS LLC (US) 2009-11-18 EP claimed
EP-1421071-B1 SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS HIGH POINT PHARMACEUTICALS LLC (US) 2009-11-18 EP disclosed
US-20080113968-A1 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2008-05-15 US disclosed
US-7208497-B2 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2007-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080113968-A1 Substituted piperazines and diazepanes HRH3, HRH4, HRH1 GPR183 264/4885GABBR2 121/4885GABBR1 137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.